133 related articles for article (PubMed ID: 37355467)
1. [Lenvatinib down-regulates IGF1R/Mek/Erk signaling pathway in the treatment of regorafenib-resistant hepatocellular carcinoma].
Zhang J; Kuang SW; Huang N; Zhang JJ; Liu M; Wang LM
Zhonghua Zhong Liu Za Zhi; 2023 Jun; 45(6):490-498. PubMed ID: 37355467
[No Abstract] [Full Text] [Related]
2. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
[TBL] [Abstract][Full Text] [Related]
3. [Inhibitory effect of IGF1R siRNA on the growth of human liver cancer SMMC7721 cell xenograft in nude mice].
Niu J; Qian HX; Li XN; Han ZG
Ai Zheng; 2007 Jul; 26(7):703-8. PubMed ID: 17626744
[TBL] [Abstract][Full Text] [Related]
4. Curcumol Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells.
Wu Z; Wang J
Discov Med; 2024 Jan; 36(180):199-208. PubMed ID: 38273760
[TBL] [Abstract][Full Text] [Related]
5. Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines.
Sasaki R; Kanda T; Fujisawa M; Matsumoto N; Masuzaki R; Ogawa M; Matsuoka S; Kuroda K; Moriyama M
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397371
[TBL] [Abstract][Full Text] [Related]
6. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
[TBL] [Abstract][Full Text] [Related]
7. [Tumor-associated macrophages promote the proliferation and migration as well as invasion of sorafenib-resistant hepatocellular carcinoma cells].
Wei X; Pu J; Guo Z; Li T; Zhu D; Wu Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 May; 33(5):617-622. PubMed ID: 28502299
[TBL] [Abstract][Full Text] [Related]
8. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice.
Weng MC; Wang MH; Tsai JJ; Kuo YC; Liu YC; Hsu FT; Wang HE
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29535278
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of extracellular signal-regulated kinase 1/2 activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells.
Yan F; Wang XM; Pan C; Ma QM
World J Gastroenterol; 2009 Mar; 15(12):1443-51. PubMed ID: 19322916
[TBL] [Abstract][Full Text] [Related]
11. [The regulation of APGAT4 on the growth and lenvatinib resistance of hepatocellular carcinoma].
Li Z; Yang NH; Li B; Sun CY
Zhonghua Gan Zang Bing Za Zhi; 2023 Apr; 31(4):408-414. PubMed ID: 37248980
[No Abstract] [Full Text] [Related]
12. Single high dose irradiation induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cells through the Ras/Raf/MEK/ERK pathways.
Tian X; Geng J; Zheng Q; Wang L; Huang P; Tong J; Zheng S
Int J Radiat Biol; 2020 Jun; 96(6):740-747. PubMed ID: 32039644
[No Abstract] [Full Text] [Related]
13. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells.
Ao J; Chiba T; Shibata S; Kurosugi A; Qiang N; Ma Y; Kan M; Iwanaga T; Sakuma T; Kanzaki H; Kanayama K; Kojima R; Kusakabe Y; Nakamura M; Saito T; Nakagawa R; Kondo T; Ogasawara S; Suzuki E; Muroyama R; Kato J; Mimura N; Kanda T; Maruyama H; Kato N
Biochem Biophys Res Commun; 2021 Apr; 549():171-178. PubMed ID: 33676186
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib.
Yang CJ; Wu MH; Tsai JJ; Hsu FT; Hsia TC; Liu KC; Kuo YC
Anticancer Res; 2022 May; 42(5):2495-2505. PubMed ID: 35489726
[TBL] [Abstract][Full Text] [Related]
15. EGF reverses multi-drug resistance via the p-ERK pathway in HepG2/ADM and SMMC7721/ADM hepatocellular carcinoma models.
Yan F; Bai LP; Gao H; Zhu CM; Lin L; Kang XP
Asian Pac J Cancer Prev; 2014; 15(6):2619-23. PubMed ID: 24761873
[TBL] [Abstract][Full Text] [Related]
16. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
[No Abstract] [Full Text] [Related]
17. Cell-cycle and apoptosis related and proteomics-based signaling pathways of human hepatoma Huh-7 cells treated by three currently used multi-RTK inhibitors.
Ren X; Zhang Q; Guo W; Wang L; Wu T; Zhang W; Liu M; Kong D
Front Pharmacol; 2022; 13():944893. PubMed ID: 36071844
[TBL] [Abstract][Full Text] [Related]
18. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.
He X; Hikiba Y; Suzuki Y; Nakamori Y; Kanemaru Y; Sugimori M; Sato T; Nozaki A; Chuma M; Maeda S
Sci Rep; 2022 May; 12(1):8007. PubMed ID: 35568782
[TBL] [Abstract][Full Text] [Related]
19. [Effect of miR-23b on the malignant phenotype and the sensitivity of lenvatinib in human hepatocellular carcinoma cells].
Yan WN; Li SB; Ma HJ; Chen DD; Wang J; Le T; Zhang GQ
Zhonghua Gan Zang Bing Za Zhi; 2021 May; 29(5):433-438. PubMed ID: 34107580
[No Abstract] [Full Text] [Related]
20. Tumor suppressor function of ezrin-radixin-moesin-binding phosphoprotein-50 through β-catenin/E-cadherin pathway in human hepatocellular cancer.
Peng XL; Ji MY; Yang ZR; Song J; Dong WG
World J Gastroenterol; 2013 Feb; 19(8):1306-13. PubMed ID: 23483729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
